TBS-2025 Cleared to Enter Post-Menin mutNPM1 AML

Company TuHURA Biosciences Event Type IND Clearance (Study May Proceed) Modality Monoclonal Antibody (VISTA Checkpoint Inhibitor) Asset TBS-2025 Target VISTA Disease Area Relapsed/Refractory Acute Myeloid Leukemia With Mutant NPM1, Post-Menin Inhibitor Summary FDA issued a “study may proceed” notice for a Phase Ib study of…